摘要
目的 证实0.2％阿法根（Alphagan）滴眼液治疗原发性开角型青光眼和高眼压症的降眼压效果及安全性。方法 选择43例原发性开角型青光眼或高眼压症患者,随机分成Alphagan组和噻吗心安（Timolol）组,2组均每日用药2次,将点第1滴药后1,2,4,6,8周的眼压与用药前的基线眼压进行对比研究,并同时观察心率和血压（收缩压与舒张压）等全身及局部不良反应。结果 每组用药后1,2,4,6,8周平均眼压与用药前平均眼压比较有显著性统计学意义（P<0.01）;每组用药后各时间点平均眼压比较无统计学意义（P>0.05）。2组用药前与用药后各时间点比较无统计学意义（P>0.05）。说明0.2％Alphagan和0.5％Timolol降眼压作用明显,而两种药的降眼压效果无显著性差异。0.2％Alphagan组无明显的局部和全身反应,而0.5％Timolol组有显著的降低心率作用。二者对血压均无明显影响。结论0.2％Alphagan与0.5％Timolol每日2次用药比较,降眼压效果显著并相似,但0.2％ Alphagan对心率无影响,可作为抗青光眼药物的一种主要选择,特别是对有心血管疾病的患者。
ve To investigate the safety and efficacy of 0. 2% Alphagan in treating primary open-angle glaucoma and ocular hypertension. Methods There were 43 patients with primary open-angle glaucoma or ocular hypertension. The patients were divided into 2 groups randomly, An Alphagan group and a Timolol group. Alphagan group was for 0. 2% Alphagan drops for twice each day and Timolol group was for 0. 5% Timolol drops for twice each day. Intraocular pressure( IOP) .heartbeat and blood pressure( systolic pressure and diastolic pressure) of the patients were evaluated before treatment and at 1 ,2 ,4 ,6 and 8 weeks after treatment. Results The average values of IOP for 1 ,2,4,6 and 8 weeks after treatment were significant differences as compared with that of baseline of IOP before treatment in Alphagan group or in Tmiolol group ( P < 0. 01 ). The ocular hypotensive efficacy in 2 groups was confirmed. There was less side-effect in topic and system in Alphagan group,but heartbeat decreased in Tmiolol group. Blood pressure was not influenced in Alphagan group or in Tmiolol group. Conclusions 0. 2% Alphagan may become a main selection in antiglaucomatous drops, especially to the patients with cardiovascular diseases.
出处
《眼科研究》
CSCD
北大核心
2002年第2期153-156,共4页
Chinese Ophthalmic Research
